Latest publications:

Graña C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, Buckley BS, Probyn K, Villanueva G, Henschke N, Bonnet H, Assi R, Menon S, Marti M, Devane D, Mallon P, Lelievre J-D, Askie LM, Kredo T, Ferrand G, Davidson M, Riveros C, Tovey D, Meerpohl JJ, Grasselli G, Rada G, Hróbjartsson A, Ravaud P, Chaimani A, Boutron I. What are the benefits and risks of vaccines for preventing COVID-19? Cochrane Database of Systematic Reviews 2022

Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, Hettiarachchi D, Mathangasinghe Y, Weeratunga P, Wickramasinghe D, Bergman H, Buckley BS, Probyn K, Sguassero Y, Davenport C, Cunningham J, Dittrich S, Emperador D, Hooft L, Leeflang MMG, McInnes MDF, Spijker R, Struyf T, Van den Bruel A, Verbakel JY, Takwoingi Y, Taylor-Phillips S, Deeks JJ. Antibody tests for identification of current and past infection with SARS‐CoV‐2. Cochrane Database of Systematic Reviews 2022

Davidson M, Menon S, Chaimani A, Evrenoglou T, Ghosn L, Graña C, Henschke N, Cogo E, Villanueva G, Ferrand G, Riveros C, Bonnet H, Kapp P, Moran C, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, Grasselli G, Tovey D, Ravaud P, Boutron I. Interleukin‐1 blocking agents for treating COVID‐19. Cochrane Database of Systematic Reviews 2022

Ghosn  L, Chaimani  A, Evrenoglou  T, Davidson  M, Graña  C, Schmucker  C, Bollig  C, Henschke  N, Sguassero  Y, Nejstgaard  CH, Menon  S, Nguyen  TV, Ferrand  G, Kapp  P, Riveros  C, Ávila  C, Devane  D, Meerpohl  JJ, Rada  G, Hróbjartsson  A, Grasselli  G, Tovey  D, Ravaud  P, Boutron  I. Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews 2021

In collaboration with Cochrane France; commissioned by WHO Health Emergencies Programme (WHE);

Cochrane Response is part of the operating team of the COVID-19 living systematic review and network meta-analysis initiatiative. COVID-NMA is an international initiative working in conjunction with the World Health Organization (WHO), led by a team of researchers from Cochrane and other institutions (Université de Paris, Inserm, CNRS, Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark, Odense University Hospital, Epistemonkos Foundation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan).

The COVID-NMA initiative has three overarching parts:

Mapping randomized controlled trials about the effectiveness of interventions for preventing and treating COVID-19 and assessing vaccines.
Living evidence syntheses of the effectiveness of treatments for COVID-19.
Recording data about the quality and transparency of the study designs.

Read more details about these parts of the initiative, and what this collaboration has been able to achieve and impact through this work in this  short case story.

Rapid reviews on treatments for COVID-19: Hydroxychloroquine

Rapid reviews on treatments for COVID-19: Lopinavir/ritonavir

In collaboration with Cochrane France; commissioned by WHO Health Emergencies Programme (WHE); We deliviered evidence summaries for these rapid reviews to the comissioner

Changing physical environments to change behaviours to reduce transmission of SARS-CoV-2

Commissioned by the UK Innovation and Research, Economic and Social Research Council; Scoping review and rapid review: Encouraging behaviour change to reduce COVID-19 transmission: A summary of two rapid evidence reviews

COVID-19 DTA rapid reviews

Contributing towards updates of the following Cochrane rapid reviews:
1. Antibody tests for identification of current and past infection with SARS-CoV-2
2. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID‐19 disease